

SEP 10 2004

**BD FACSCanto System with BD FACSDiva software 510(k) Summary**

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of Safe Medical Devices Act of 1990 and 21 CFR 807.92.

The assigned 510(k) number is K040725.

***Submitter Information (21 CFR 807.92(a)(1))***

Submitter: Becton Dickinson Immunocytometry Systems  
2350 Qume Drive  
San Jose, CA 95131

Contact: Kim Fonda  
Sr. Regulatory Affairs Specialist  
(408) 954-2329  
(408) 954-2495 (FAX)  
kim\_fonda@bd.com

Summary date: March 19, 2004

***Device Name and Classification (21 CFR 807.92(a)(2))***

Name: BD FACSCanto™ System with BD FACSDiva™ software  
Classification: Class II (21 CFR 864.5220), Automated differential cell counter

***Substantially Equivalent / Predicate Device (21 CFR 807.92(a)(3))***

The BD FACSCanto System with BD FACSDiva software is substantially equivalent to the BD FACSCalibur™ with 4-color option for immunophenotyping using SimulTEST reagents and associated software. FACSCalibur 4-color instrument was cleared with FACSComp Software and CaliBRITE Beads by the Center for Devices and Radiological Health, under K973483 on 2/17/98. The BD FACSCanto System with BD FACSDiva software and BD FACSCalibur have similar intended uses, measure the same sample types and have similar performance characteristics.

***Device Description (21 CFR 807.92(a)(4))***

The BD FACSCanto System with BD FACSDiva software is comprised of a flow cytometer, a wet cart, and a computer. The wet cart contains operational fluids, the flow cytometer acquires and analyzes the sample, and the computer displays and prints the analysis. The flow cytometer utilizes three sub-systems; fluidics, optics and electronics. It contains one software package for

manual immunophenotyping and is compatible with the BD FACSLoader for automatic sample introduction.

***Intended Use (21 CFR 807.92(a)(5))***

The BD FACSCanto System with BD FACSDiva software is intended for use as an In Vitro Diagnostic device for identification and enumeration of lymphocyte subsets in human cells in suspension using a lyse wash sample preparation method for flow cytometry.

***Technological Characteristics (21 CFR 807.92(a)(6))***

The following summary table describes the similarities and differences between the BD FACSCanto and the BD FACSCalibur.

<b>Characteristic</b>	<b>FACSCalibur System (predicate)</b>	<b>BD FACSCanto System with BD FACSDiva software (new family member)</b>
Intended Use	For identification and enumeration of leucocyte subsets in human cells in suspension	For identification and enumeration of lymphocyte subsets in human cells in suspension using a lyse wash sample preparation method for flow cytometry.
Device classification and product code	Automated Differential Cell Counter 21 CFR 864.5220 Product Code: GKZ	Same
Lasers	Blue—488 nm argon ion Red—635 nm diode laser	488 nm solid state 633 nm HeNe
Detectors	1 FSC photodiode 1 SSC photomultiplier tube (PMT) 4 fluorescence detector PMTs	Same FSC Same SSC Same 4 plus 2 additional fluorescence detector PMTs
Optics	FACSCalibur flow cell  Laser light delivered by mirrors, prisms and lenses Emitted light delivered by mirrors	Same  Laser light delivered by fiber optics, prisms and lasers Emitted light delivered by collection and fiber optics
Electronics	Analog	Digital
Automated sample introduction	FACS Loader: K953302, 11/20/95	Same

<b>Characteristic</b>	<b>FACSCalibur System (predicate)</b>	<b>BD FACSCanto System with BD FACSDiva software (new family member)</b>
Computer platform	Macintosh	PC

***Performance Data (21 CFR 807.92(b)(1) and (2))***

<b>Study</b>	<b>Study Design</b>	<b>Results</b>
Accuracy	Based on NCCLS document EP9-A2. (September 2002)	The BD FACSCanto demonstrated comparable accuracy relative to the predicate.
Precision	Based on NCCLS document EP5-A. (February 1999)	The BD FACSCanto demonstrated acceptable system precision.
Carryover	Based on recommendations contained in "Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA." (December 4, 2001)	The BD FACSCanto demonstrated acceptable system carryover.
Linearity	Based on recommendations contained in "Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA." (December 4, 2001)	The BD FACSCanto demonstrated acceptable system linearity.

***Conclusions from Performance Data (21 CFR 807.92(b)(3))***

The BD FACSCanto System with BD FACSDiva software demonstrates substantial equivalence to the predicate device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Ms. Kim Fonda  
Sr. Regulatory Affairs Specialist  
Becton Dickinson Immunocytometry Systems  
2350 Qume Drive  
San Jose, CA 95131

SEP 10 2004

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Re: k040725  
Trade/Device Name: BD FACSCanto System with BD FACSDiva software  
Regulation Number: 21 CFR 864.5220  
Regulation Name: Automated differential cell counter  
Regulatory Class: Class II  
Product Code: GKZ  
Dated: August 4, 2004  
Received: August 6, 2004

Dear Ms. Fonda

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Robert L. Becker, Jr.", written in a cursive style.

Robert L. Becker, Jr., M.D., Ph.D.

Director

Division of Immunology and Hematology Devices

Office of In Vitro Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

**Indications for Use**

**510(k) Number:** K040725

**Device Name:** BD FACSCanto System with BD FACSDiva software

**Indications for Use:**

- Immunophenotyping in clinical laboratories, using previously cleared IVD assays for flow cytometry that utilize the lyse wash sample preparation method.
- Immunophenotyping of lymphocyte subsets including CD3<sup>+</sup>CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, CD3<sup>-</sup>CD16<sup>+</sup> and/or CD56<sup>+</sup>, CD3<sup>-</sup>CD19<sup>+</sup>, and CD3<sup>+</sup>.


**Clinical Significance:**

- For In Vitro Diagnostic Use.

Prescription Use   X   AND/OR Over-The-Counter Use             
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE  
CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
Division Sign/Off

Page \_\_\_ of \_\_\_

**Office of In Vitro Diagnostic Device  
Evaluation and Safety**

510(k)   K040725